I 
109TH CONGRESS 
1ST SESSION H. R. 2574 
To amend the Public Health Service Act to provide for a program at the 
National Institutes of Health to conduct and support research on animals 
to develop techniques for the derivation of stem cells from embryos 
that do not harm the embryos, and for other purposes. 
IN THE HOUSE OF REPRESENTATIVES 
MAY 24, 2005 
Mr. BARTLETT of Maryland (for himself, Mr. GINGREY, Mr. NORWOOD, Mr. 
OSBORNE, Mr. CULBERSON, Mr. ENGLISH of Pennsylvania, Mr. ROHR-
ABACHER, Mr. PRICE of Georgia, and Mr. CANNON) introduced the fol-
lowing bill; which was referred to the Committee on Energy and Com-
merce 
A BILL 
To amend the Public Health Service Act to provide for 
a program at the National Institutes of Health to con-
duct and support research on animals to develop tech-
niques for the derivation of stem cells from embryos 
that do not harm the embryos, and for other purposes. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Respect for Life Em-
bryonic Stem Cell Act of 2005’’.
SEC. 2. FINDINGS. 
The Congress finds as follows: 
(1) The President’s Council on Bioethics in its 
May 2005 White Paper: ‘‘Alternative Sources of 
Pluripotent 
Stem 
Cells,’’ 
acknowledges 
that 
pluripotent stem cell lines might be derived from an 
early stage human embryo without harming the em-
bryo’s prospects for developing into a baby. 
(2) Identical twinning occurs spontaneously in 
nature during at least two stages of the in vivo 
human development process demonstrating the via-
bility and feasibility of the removal of some cells 
from an early stage human embryo without harming 
the embryo’s ability to develop into a baby. 
(3) The removal of some cells from living 
human embryos is already occurring to conduct 
preimplantation genetic diagnosis (‘‘PGD’’). PGD is 
a procedure increasingly offered to individuals seek-
ing to become parents as an option in conjunction 
with assisted reproductive technologies to diagnose 
their embryos created through in vitro fertilization 
(‘‘IVF’’) for genetic and chromosomal abnormalities 
prior to implantation and pregnancy. 
(4) There have been reports that more than 
1,000 babies have been born worldwide and more
than 150 babies have been born in the United States 
after undergoing PGD as early stage embryos. 
(5) IVF to create and PGD to diagnose early 
stage human embryos is proceeding without Federal 
funding. 
(6) There is no Federal prohibition against 
using IVF to create or PGD to diagnose early stage 
human embryos. 
(7) Informed parental consent is obtained and 
granted by individuals to utilize IVF and PGD on 
behalf of themselves and to benefit their children. 
(8) Cells removed for PGD from an early stage 
human embryo might be cultured to produce and 
store a stock of cells that could become a genetically 
matched repair kit for that individual. 
(9) Surplus cells from an individual’s repair kit 
might be used to establish an embryonic stem cell 
line made available for basic and applied research to 
develop treatments for debilitating and deadly 
human ailments. 
(10) Individuals seeking to become parents who 
have already chosen and committed to use PGD and 
establish a repair kit for the benefit of their children 
could have the option to donate surplus cells from
their children’s repair kit for the establishment of a 
new embryonic stem cell line. 
SEC. 3. DERIVATION OF STEM CELLS WITHOUT HARMING 
EMBRYOS; ANIMAL RESEARCH THROUGH NA-
TIONAL INSTITUTES OF HEALTH. 
Part B of title IV of the Public Health Service Act 
(42 U.S.C 284) is amended by adding at the end the fol-
lowing: 
‘‘SEC. 409J. BASIC AND APPLIED RESEARCH ON DERIVA-
TION OF STEM CELLS WITHOUT HARMING 
EMBRYOS. 
‘‘(a) IN GENERAL.—With respect to producing stem 
cell lines for research on treatments for diseases and other 
adverse health conditions, the Director of NIH shall, 
through the appropriate national research institutes, pro-
vide for the conduct and support of basic and applied re-
search— 
‘‘(1) to develop techniques for the derivation of 
stem cells from embryos that do not harm the em-
bryos; and 
‘‘(2) in the case of stem cells that are derived 
without harming the embryo, to develop techniques 
for storing the stem cells for the possibility that in 
the future a therapy may be developed that uses the
stem cells of an animal to adapt the therapy to that 
particular animal. 
‘‘(b) PROHIBITIONS
REGARDING
CLINICAL
RE-
SEARCH.—Research under subsection (a) may not include 
clinical research, and may not include any research that— 
‘‘(1) involves the derivation of stem cells from 
human embryos; or 
‘‘(2) uses any stem cell to create or to attempt 
to create a human embryo. 
‘‘(c) AUTHORIZATION OF APPROPRIATIONS.—For the 
purpose of carrying out this section, there is authorized 
to be appropriated $10,000,000 in the aggregate for the 
fiscal years 2006 through 2010.’’. 
Æ